Glossary of terms used in Pharmacovigilance

**Absolute risk**
Risk in a population of exposed persons; the probability of an event affecting members of a particular population (e.g. 1 in 1,000). Absolute risk can be measured over time (incidence) or at a given time (prevalence). Also see **Attributable risk** and **Relative risk**.

**Adverse Event (AE)**
Any untoward medical occurrence that may present during treatment with a pharmaceutical product but which does not necessarily have a causal relationship with this treatment. Also see **Adverse reaction** and **Side Effect**.

**Adverse (Drug) Reaction (ADR)**
A response which is noxious and unintended, and which occurs at doses normally used in humans for the prophylaxis, diagnosis, or therapy of disease, or for the modification of physiological function. (WHO, 1972).
An adverse drug reaction, contrary to an adverse event, is characterized by the suspicion of a causal relationship between the drug and the occurrence, i.e. judged as being at least possibly related to treatment by the reporting or a reviewing health professional.

In the **EU Directive 2010/84**, which will become applicable in July 2012 an adverse reaction is defined as:
A response to a medicinal product which is noxious and unintended.

**Allopathy**
Non-traditional, western scientific therapy, usually using synthesised ingredients, but may also contain a purified active ingredient extracted from a plant or other natural source; usually in opposition to the disease. Also see **Homeopathy**.

**Association**
Events associated in time but not necessarily linked as cause and effect.

**Attributable risk**
Difference between the risk in an exposed population (**absolute risk**) and the risk in an unexposed population (**reference risk**). Also referred to as **Excess risk**.

Attributable risk is the result of an absolute comparison between outcome frequency measurements, such as incidence.

**Benefit**
An estimated gain for an individual or a population. Also see **Effectiveness/Risk**.

**Benefit - risk analysis**
Examination of the favourable (beneficial) and unfavourable results of undertaking a specific course of action. (While this phrase is still commonly used, the more logical pairings of benefit-harm and effectiveness-risk are slowly replacing it).

**Biological products**
Medical products prepared from biological material of human, animal or microbiologic origin (such as blood products, vaccines, insulin).

**Causal relationship**
A relationship between one phenomenon or event (A) and another (B) in which A precedes and causes B. In pharmacovigilance; a medicine causing an adverse reaction.

**Causality assessment**
The evaluation of the likelihood that a medicine was the causative agent of an observed adverse reaction. Causality assessment is usually made according established algorithms.

**Caveat document**
The formal advisory warning accompanying data release from the WHO Global ICSR Database: it specifies the conditions and reservations applying to interpretations and use of the data.

**CemFlow**
Software developed by UMC for collection and analysis of data in Cohort Event Monitoring. Also see **Cohort Event Monitoring**.

**Clinical trial**
A systematic study on pharmaceutical products in human subjects (including patients and other volunteers) in order to discover or verify the effects of and/or identify any adverse reaction to investigational products, and/or to study the absorption, distribution, metabolism and excretion of the products with the objective of ascertaining their efficacy and safety.
**Cohort Event Monitoring**  
Cohort Event Monitoring (CEM) is a prospective, observational study of events that occur during the use of medicines, for intensified follow-up of selected medicinal products phase. Patients are monitored from the time they begin treatment, and for a defined period of time. See also **Prescription Event Monitoring**.

**Compliance**  
Faithful adherence by the patient to the prescriber's instructions.

**Control group**  
The comparison group in drug-trials not being given the studied drug.

**Critical terms**  
Some of the terms in WHO-ART are marked as ‘Critical Terms’. These terms either refer to or might be indicative of serious disease states, and warrant special attention, because of their possible association with the risk of serious illness which may lead to more decisive action than reports on other terms.  
Also see **Serious adverse event or reaction**.

**Data mining**  
A general term for computerised extraction of potentially interesting patterns from large data sets, often based on statistical algorithms. A related term with essentially the same meaning is ‘pattern discovery’. In pharmacovigilance, the commonest application of data mining is so called disproportionality analysis, for example using the Information component (IC). See also **Disproportionality analysis**, **Information component**, **Omega**.

**Dechallenge**  
The withdrawal of a drug from a patient; the point at which the continuity, reduction or disappearance of adverse effects may be observed.

**Disproportionality analysis**  
Screening of ICSR databases for reporting rates which are higher than expected. For drug-ADR pairs, common measures of disproportionality are the Proportional Reporting Ratio (PRR), the Reporting Odds Ratio (ROR), The Information Component (IC), and the Empirical Bayes Geometrical Mean (EBGM). There are also disproportionality measures for drug-drug-ADR triplets, such as Omega (Ω). See also **Information component**, **Omega**.

**Effectiveness/risk**  
The balance between the rate of effectiveness of a medicine versus the risk of harm is a quantitative assessment of the merit of a medicine used in routine clinical practice. Comparative information between therapies is most useful. This is more useful than the efficacy and hazard predictions from pre-marketing information that is limited and based on selected subjects.

**Efficacy**  
The ability of a drug to produce the intended effect as determined by scientific methods, for example in pre-clinical research conditions (opposite of hazard). See also **Absolute risk**, **Reference risk**, **Attributable risk** and **Relative risk**.

**Epidemiology**  
The science concerned with the study of the factors determining and influencing the frequency and distribution of disease, injury and other health-related events and their causes in a defined human population for the purpose of establishing programs to prevent and control their development and spread (Dorland’s Illustrated Medical Dictionary). Also see **Pharmacoepidemiology**.

**Essential medicines**  
Essential medicines are those that satisfy the priority health care needs of the population. They are selected with due regard to public health relevance, evidence on efficacy and safety, and comparative cost-effectiveness. See http://www.who.int/selection_medicines/en/

**EudraVigilance**  
The European Union data-processing network and management system, established by the European Medicines Agency (EMA) to support the electronic exchange, management, and scientific evaluation of Individual Case Safety Reports related to all medicinal products authorised in the European Economic Area (EEA). EudraVigilance also incorporates data analysis facilities.

**Excipients**  
All materials included to make a pharmaceutical formulation (e.g. a tablet) except the active drug substance(s).
Formulary
A listing of medicinal drugs with their uses, methods of administration, available dose forms, side effects, etc, sometimes including their formulas and methods of preparation.

Frequency of ADRs
In giving an estimate of the frequency of ADRs the following standard categories are recommended:
- Very common* > 10%
- Common (frequent) > 1% and < 10%
- Uncommon (infrequent) > 0.1% and < 1%
- Rare > 0.01% and < 1%
- Very rare* < 0.01%
* Optional categories

Generic (multisource product)
The term ‘generic product’ has somewhat different meanings in different jurisdictions. Generic products may be marketed either under the non-proprietary approved name or under a new brand (proprietary) name. They are usually intended to be interchangeable with the innovator product, which is usually manufactured without a license from the innovator company and marketed after the expiry of patent or other exclusivity rights.

Harm
The nature and extent of actual damage that could be caused by a drug. Not to be confused with risk.

Herbal medicine
Includes herbs, herbal materials, herbal preparations and finished herbal products.

Homeopathy
Homeopathy is a therapeutic system which works on the principle that ‘like treats like’. An illness is treated with a medicine which could produce similar symptoms in a healthy person. The active ingredients are given in highly diluted form to avoid toxicity. Homeopathic remedies are virtually 100% safe. Also see Allopathy.

Information component (IC)
The Information component (IC) measures the disproportionality in the reporting of a drug-ADR pair in an ICSR database, relative to the reporting expected based on the overall reporting of the drug and the ADR. Positive IC values indicate higher reporting than expected. The IC has also been implemented on electronic health records, to detect interesting temporal relationships between drug prescriptions and medical events.

Incidence
Number of new cases of an outcome which develop over a defined time period in a defined population at risk.

Individual Case Safety Report (ICSR)
A report that contains ‘information describing a suspected adverse drug reaction related to the administration of one or more medicinal products to an individual patient…’. (Volume 9 of the Rules Governing Medicinal Products for Human and Veterinary Use in the European Union).

MedDRA
MedDRA is the Medical Dictionary for Regulatory Activities. WHO-ART, the WHO Adverse Reactions Terminology, is now mapped to MedDRA.

Medical error
“An unintended act (either of omission or commission) or one that does not achieve its intended outcomes.” Leape, Lucien. Error in Medicine. Journal of the American Medical Association 272(23):1851-57 (Dec. 21, 1994).

Member countries
Countries which comply with the criteria for, and have joined the WHO Programme for International Drug Monitoring.

National pharmacovigilance centres
Organisations recognised by governments to represent their country in the WHO Programme (usually the drug regulatory agency). A single, governmentally recognized centre (or integrated system) within a country with the clinical and scientific expertise to collect, collate, analyse and give advice on all information related to drug safety.

Odds
Probability of an occurrence $p$ divided by the probability of its non-occurrence ($1 - p$).

Odds ratio
Ratio of the Odds in a given population and the Odds in another population.
**Omega (Ω)**
A measure of disproportionate reporting for drug-drug-ADR triplets in ICSR databases, designed to highlight potential signals of drug-drug interactions. Just like the more established disproportionality measures for drug-ADR pairs, Ω is based on a contrast between the observed and expected number of reports. A positive Ω indicates higher reporting than expected.

**OTC (Over The Counter) medicine**
Medicinal product available to the public without prescription.

**PaniFlow**
Software developed by UMC for collection and analysis of data in relation to vaccinations in a pandemic situation.

**Periodic Safety Update Report (PSUR)**
A systematic review of the global safety data which became available to the manufacturer of a marketed drug during a specific time period. Produced in an internationally agreed format.

**Pharmacoepidemiology**
Study of the use and effects of drugs in large populations. Also see Epidemiology.

**Pharmacology**
Study of the uses, effects and modes of action of drugs.

**Pharmacovigilance**
The science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem.

**Phocomelia**
Characteristic deformity caused by exposure to thalidomide in the womb, also very rarely occurring spontaneously. Meaning: limbs like a seal.

**Phytotherapy**
Western-style, scientific treatment using plant extracts or materials.

**Placebo**
An inactive substance (often called a sugar pill) given to a group being studied to compare results with the effects of the active drug.

**Polypharmacy**
The concomitant use of more than one drug, sometimes prescribed by different practitioners.

**Post-marketing**
The stage when a drug is generally available on the market.

**Predisposing factors**
Any aspect of the patient’s history (other than the drug) which might explain reported adverse events (genetic factors, diet, alcohol consumption, disease history, polypharmacy or use of herbal medicines, for example).

**Pre-marketing**
The stage before a drug is available for prescription or sale to the public.

**Prescription Event Monitoring (PEM)**
System created to monitor adverse drug events in a population. Prescribers are requested to report all events, regardless of whether they are suspected adverse events, for identified patients receiving a specified drug. Also more accurately named Cohort Event Monitoring.

**Prescription Only Medicine (POM)**
Medicinal product available to the public only on prescription.

**Prevalence**
Number of existing cases of an outcome in a defined population at a given point in time.

**Prophylaxis**
Prevention or protection.

**Rational drug use**
An ideal of therapeutic practice in which drugs are prescribed and used in exact accordance with the best understanding of their appropriateness for the indication and the particular patient, and of their benefit, harm effectiveness and risk.

**Rechallenge**
The point at which a drug is again given to a patient after its previous withdrawal - also see dechallenge.

**Record linkage**
Method of assembling information contained in two or more records, eg in different sets of medical charts, and in vital records such as birth and death certificates. This makes it possible to relate significant health events that are remote from one another in time and place.
**Reference risk**
Risk in a population of unexposed persons; also called baseline risk. Reference risk can be measured over time (incidence) or at a given time (prevalence). The unexposed population refers to a reference population, as closely comparable to the exposed population as possible, apart from the exposure.

**Regulatory authority**
The legal authority in any country with the responsibility of regulating all matters relating to drugs.

**Relative risk**
Ratio of the risk in an exposed population (absolute risk) and the risk in an unexposed population (reference risk). Relative risk is the result of a relative comparison between outcome frequency measurements, e.g. incidences.

**Risk**
The probability of harm being caused; the probability (chance, odds) of an occurrence.

**Serious Adverse Event or Reaction**
A serious adverse event or reaction is any untoward medical occurrence that at any dose:

- results in death
- requires inpatient hospitalisation or prolongation of existing hospitalisation
- results in persistent or significant disability/incapacity
- is life-threatening

To ensure no confusion or misunderstanding of the difference between the terms ‘serious’ and ‘severe’, the following note of clarification is provided:
The term ‘severe’ is not synonymous with serious. In the English language, ‘severe’ is used to describe the intensity (severity) of a specific event (as in mild, moderate or severe); the event itself, however, may be of relatively minor medical significance (such as severe headache). Seriousness (not severity) which is based on patient/event outcome or action criteria serves as guide for defining regulatory reporting obligations.

**Side effect**
Any unintended effect of a pharmaceutical product occurring at normal dosage which is related to the pharmacological properties of the drug.

**Signal**
Reported information on a possible causal relationship between an adverse event and a drug, the relationship being unknown or incompletely documented previously. Usually more than a single report is required to generate a signal, depending upon the seriousness of the event and the quality of the information. The publication of a signal usually implies the need for some kind of review or action.

**Summary of Product Characteristics (SPC)**
A regulatory document attached to the marketing authorization which forms the basis of the product information made available to prescribers and patients.

**Spontaneous reporting**
System whereby case reports of adverse drug events are voluntarily submitted from health professionals and pharmaceutical manufacturers to the national regulatory authority. Also see ICSR.

**Thalidomide**
Drug prescribed in the 1950s as a mild sleeping pill and remedy for morning-sickness for pregnant women. Led to serious birth defects and the start of modern pharmacovigilance. Returning to favour in treatment of serious diseases such as cancer and leprosy.

**Traditional medicines**
Traditional medicine is the sum total of the knowledge, skills, and practices based on the theories, beliefs, and experiences indigenous to different cultures, whether explicable or not, used in the maintenance of health as well as in the prevention, diagnosis, improvement or treatment of physical and mental illness. Also see Allopathic medicine.

**Unexpected adverse reaction**
An adverse reaction, the nature or severity of which is not consistent with domestic labelling or market authorization, or expected from characteristics of the drug.

**VigiBase**
The name of the WHO Global ICSR Database.
**VigiFlow**
VigiFlow is a complete ICSR management system created and maintained by the UMC. It is web-based and built to adhere to the ICH-E2B standard. It can be used as the national database for countries in the WHO Programme as it incorporates tools for report analysis, and facilitates sending reports to VigiBase.

**Vigimed**
Sharepoint based conferencing facility, exclusive to member countries of the WHO Programme for International Drug Monitoring for fast communication of topical pharmacovigilance issues.

**VigiMine**
A statistical tool within VigiSearch with vast statistical material calculated for all Drug-ADR pairs (combinations) available in VigiBase. The main features include the disproportionality measure (IC value) stratified in different ways and useful filter capabilities.

**VigiSearch**
A search service for accessing ICSRs stored in the VigiBase database offered by the UMC to national pharmacovigilance centres and other third-party inquirers.

**WHO-ART**
Terminology for coding clinical information in relation to drug therapy. WHO-ART is maintained by UMC.

**WHO Drug Dictionary (WHO DD)**
The WHO Drug Dictionary is an international classification of drugs providing proprietary and on-proprietary names of medicinal products used in different countries, together with all active ingredients.